This conclusion is supported by the observation that persistent ERK1/2 activation is found in a wide range of patient-derived mammary tumor cell lines, many of which do not harbor amplified expression of ErbB2 [43] and the sequencing of breast cancer tumor genomes [5]. This evidence concerns the gene MAPK3 and breast cancer.